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OBJECTIVES Our hypothesis was that functional polymorphisms in matrix metalloproteinase (MMP)
genes may act as susceptibility factors for the development of coronary aneurysms (CAs).
BACKGROUND Different forms of remodeling have been described at the level of coronary arteries; CA,
reported in 1% to 5% of patients with angiographic evidence of coronary artery disease
(CAD), are one of them. Matrix metalloproteinases have been implicated in the pathogenesis
of aneurysm development through increased proteolysis of extracellular matrix proteins.
METHODS We screened 3,862 patients who underwent coronary angiography and identified 113 patients
with CAD with at least one CA (CA group); these patients were matched with 226 patients
with CAD without CA (control group). The 1,306 C/T MMP-2, 5A/6A MMP-3,
CA-repeat MMP-9 and 82 A/G MMP-12 polymorphisms were determined.
RESULTS The MMP-2, MMP-9 and MMP-12 polymorphisms were not associated with CA. By
contrast, the 5A/5A genotype of MMP-3 was significantly more frequent in the CA group
than in the control group (31% vs. 18%, p  0.015); similarly, the MMP-3 5A allele was
more frequent in the CA group (p  0.009). Three variables were independently associated
with CA: the MMP-3 5A/5A genotype (odds ratio [OR]  2.23, 95% confidence interval
[CI] [1.27 to 3.93]), a previous myocardial infarction (OR  1.91, 95% CI [1.14 to 3.20])
and a history of aortic aneurysm (OR  21.06, 95% CI [2.35 to 188]).
CONCLUSIONS The MMP-3 5A allele is associated with the occurrence of CA. Our results suggest that an
increased proteolysis in the arterial wall may act as a susceptibility factor for the development
of CA in patients with coronary atherosclerosis. (J Am Coll Cardiol 2002;40:43–8) © 2002
by the American College of Cardiology Foundation
Although experimental and clinical studies have provided
important insights into the pathogenesis of coronary ath-
erosclerosis, many questions remain to be elucidated. The
development of atherosclerosis is commonly associated with
coronary stenosis and/or thrombosis, which, in turn, may
lead to angina pectoris and/or myocardial infarction (MI)
(1). Aneurysms may also occur during the course of coro-
nary atherosclerosis. Previous studies have shown that cor-
onary aneurysms (CAs) are observed in 1% to 5% of patients
with angiographic evidence of coronary artery disease
(CAD) (2–5); in some studies, CAs have been associated
with an increased risk of MI (2,3). The mechanisms
responsible for CA formation during the atherosclerotic
process are unknown. A better knowledge of the factors that
may determine this abnormal remodeling of the vascular
wall would help to understand the responses of coronary
arteries to the atherosclerotic process.
Studies performed in patients with aortic aneurysms may
offer some insights into the general pathogenesis of aneu-
rysms. The matrix metalloproteinases (MMPs) have been
implicated in the development of aortic aneurysms through
increased proteolysis of extracellular matrix proteins (6).
Previous studies have found that MMP-1 (interstitial col-
lagenase), MMP-2 (72-kD gelatinase or gelatinase A),
MMP-3 (stromelysin-1), MMP-9 (92-kD gelatinase or
gelatinase B) and MMP-12 (macrophage metalloelastase)
are expressed in aortic aneurysms at elevated levels com-
pared with normal vessel wall (6–10). This arsenal of
MMPs has the capacity to degrade virtually all components
of the extracellular matrix in the arterial wall (collagens,
elastin, proteoglycans, laminin, fibronectin, etc.). On the
other hand, a decreased level of tissue inhibitor of metallo-
proteinases (TIMP) has been reported in aortic aneurysms
(9,11). Moreover, in experimental models, inhibitors of
MMPs (12), MMPs gene disruption (13,14) or the overex-
pression of TIMP-1 (15) may block aneurysm development.
Our study hypothesis was that a genetic-mediated in-
creased proteolysis in the arterial wall may act as a suscep-
tibility factor for the development of CA in patients with
coronary atherosclerosis. Four candidate genes were se-
lected: MMP-2, MMP-3, MMP-9 and MMP-12. Poly-
morphisms described in the promoters of these four genes
are functional because they exhibit different transcriptional
activities in vitro (16–20) and were implicated in different in
vivo studies (18,19,21–23). They may, consequently, play a
role in the regulation of extracellular matrix proteolysis.
Thus, we designed the present case/control study to com-
pare allele and genotype frequencies among 113 patients
with atherosclerotic CA and 226 control patients with
coronary atherosclerosis but without aneurysm formation.
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MATERIALS AND METHODS
Study population. The study population was prospectively
selected from a series of 3,862 consecutive patients who
underwent coronary angiography at Centre Hospitalier
Universitaire de Lille. A CA was defined as a localized or
diffuse coronary dilation that exceeded the diameter of the
angiographically apparently normal adjacent segments by a
factor of1.5 (3). A total of 113 patients with angiographi-
cally proven coronary atherosclerosis who had at least one
CA constitute the CA group. During the same period, we
randomly selected 226 patients (2:1 ratio) who presented
with coronary atherosclerosis, but without CA, to form the
atherosclerotic control group. All patients gave informed
consent for the study.
Clinical and angiographic data. Epidemiological and
clinical characteristics were collected by trained physicians.
Coronary angiograms were analyzed by two experienced
interventional cardiologists. The number of nonsignificant
(50%) or significant (50%) stenoses was recorded for
each patient. The extent of aneurysmal disease (number of
diseased segments and of diseased vessels per patient) was
also noted as was the type (diffuse or focal) of CA.
Aneurysmal disease was classified as focal when it involved
a discrete portion of a segment with adjacent normal
appearing segments on both sides and diffuse when the
entire segment was dilated with no normal vessel within the
segment.
The largest diameter of each aneurysmal vessel was
measured by quantitative coronary angiography with use of
the cardiovascular measurement system as previously de-
scribed (24).
Genetic study. Blood samples were collected at the time of
coronary angiography. Genomic deoxyribonucleic acid was
extracted from white blood cells by a “salting out” procedure
as previously described (25). Deoxyribonucleic acid frag-
ment amplification was performed by polymerase chain
reaction (PCR). Primers and PCR conditions used for
MMP-3 (17,18) have been reported previously. The prim-
ers used in 1,306 C/T MMP-2 PCR (sense 5-
TGTTGGGAACGCCTGACTTCAG-3 and antisense
5-CTGACCCCCAGTCCTATCTGCC-3), CA-repeat
MMP-9 PCR (sense 5-GAGAGAGGAGGAGGTGG-
TGTAAG-3 and antisense 5-TGACAGGCAAGTG-
CTGACTC-3) and in 82 A/G MMP-12 PCR (sense
5-AAGAGCTCCAGAAGCAGTGG-3 and antisense
5-TGAGGTGGGTAAGAGTACAATGG-3) were
designed from the DNA sequence surrounding the poly-
morphism. Annealing temperatures were 58°C (MMP-2),
56°C (MMP-9) and 59°C (MMP-12). The 1,306
MMP-2, 5A/6A MMP-3 and the 82 A/G MMP-12
polymorphisms were detected using allele-specific oligonucle-
otide hybridization with the following probes (polymorphism
underlined): wild-type probe 5-AGCACTCCACC-
TCTT-3 and mutated probe 5-AGCACTCTACC-
TCTT-3 for MMP-2 (hybridization at 40°C and washing
at 42°C), 5A-probe 5-ACATGGTTTTTCCC-3 and
6A-probe 5-GGGAAAAAACCATG-3 for MMP-3
(hybridization at 35°C and washing at 37°C) and wild-type
probe 5-TATCAACTATGAGTCAC-3 and mutated
probe 5-ATCAACTGTGAGTCAC-3 for MMP-12
(hybridization at 43°C, washings at 47°C and 45°C, respec-
tively). The MMP-9 polymorphism, a CA-repeat, was
analyzed by PCR, and fragments were separated on 8%
nondenaturated acrylamide gel, as previously described (26).
Statistical analysis. Statistical analysis was performed with
SAS software, version 6.12 (SAS Institute Inc., Cary, North
Carolina). Mean values  SD were calculated for quanti-
tative data. The quantitative variables were compared be-
tween groups with use of unpaired Student t tests. Quali-
tative variables were compared with use of the Pearson’s
chi-square test or the Fisher exact test when necessary.
Logistic regression analysis was used to determine variables
that were independently associated with aneurysmal CAD.
Values of p  0.05 were considered significant.
RESULTS
Except for male gender, previous MI and an history of aortic
aneurysm, which were significantly more frequent in the
CA group (90% vs. 80%, p  0.017; 68% vs. 52%, p 
0.005 and 7% vs. 0.4%, p  0.0003, respectively), the
baseline characteristics were similarly distributed in both
groups (Table 1).
Representative examples of CA are shown in Figure 1.
Abbreviations and Acronyms
CA  coronary aneurysm
CAD  coronary artery disease
CI  confidence interval
MI  myocardial infarction
MMP  matrix metalloproteinase
OR  odds ratio
PCR  polymerase chain reaction
TIMP  tissue inhibitor of metalloproteinases
Table 1. Baseline Characteristics of the Study Population
CA
(n  113)
Controls
(n  226)
p
Value
Age, yrs 62  12 62  11 0.76
BMI, kg/m2 27.2  4.1 27.6  4.2 0.63
Male gender 102 (90%) 181 (80%) 0.017
Smoking 89 (79%) 158 (70%) 0.08
Hypercholesterolemia 91 (81%) 171 (76%) 0.31
Hypertension 49 (43%) 112 (50%) 0.28
Diabetes 18 (16%) 56 (25%) 0.06
Previous MI 77 (68%) 118 (52%) 0.005
Aortic aneurysm* 8 (7%) 1 (0.4%) 0.0003
Number of lesions
Nonsignificant 6 (5%) 21 (9%)
Single-vessel 30 (27%) 76 (34%) 0.068
Two-vessel 50 (45%) 73 (32%)
Three-vessel 25 (23%) 56 (25%)
*Such as history of aortic aneurysm (systematic screening was not performed).
BMI  body mass index; CA  coronary aneurysm; MI  myocardial infarction.
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The most frequent location of CA was the right coronary
artery (Table 2). Approximately half of the patients had
aneurysmal involvement of more than one coronary vessel;
the mean number of involved segments per patient was
3.2 1.9. In most cases, CAs were classified as diffuse. The
maximal diameter of the aneurysmal segments was 6.6 
1.2 mm (range 4.7 to 11.6 mm).
The results of the genetic analyses are presented in Tables
3 and 4. The distributions of the MMP-2, MMP-3,
MMP-9 and MMP-12 genotypes were compatible with
those expected from the Hardy-Weinberg equilibrium. The
5A/5A genotype of MMP-3 was significantly more fre-
quent in the CA group than in the control group (31% vs.
18%, p  0.015); similarly, the MMP-3 5A allele was more
Figure 1. Representative examples of coronary aneurysms. (A) Diffuse
aneurysmal disease of the right coronary (maximal diameter: 6.8 mm). (B)
Diffuse aneurysmal disease of the proximal and midleft anterior descending
artery (maximal diameter: 9.3 mm). (C) Focal aneurysm of the proximal
right coronary artery (arrow) (maximal diameter: 11.6 mm).
Table 2. Angiographic Characteristics of the Patients With
Coronary Aneurysm
Aneurysm(s) location
Left main 8 (7%)
Left anterior descending artery 58 (52%)
Circumflex 43 (39%)
Right coronary artery 80 (72%)
Number of vessel(s) with aneurysm(s)
1 57 (52%)
2 36 (32%)
3 18 (16%)
Number of coronary segments with aneurysm(s) 3.2  1.9
Patients with more than
2 aneurysmal coronary segments 64 (57%)
3 aneurysmal coronary segments 41 (36%)
Type of aneurysm
Diffuse 92 (83%)
Focal 21 (17%)
Maximal diameter of aneurysmal segments (mm)
Left main 6.9  1.3
Left anterior descending artery 5.9  1.2
Circumflex 5.7  0.7
Right coronary artery 6.4  1.3
Table 3. MMP-2, MMP-3 and MMP-12 Genotypes
and Alleles
Gene
Genotype/
Allele
CA
n (Fraction)
Controls
n (Fraction) p Value
MMP-2 CC 78 (0.69) 138 (0.61)
CT 32 (0.28) 73 (0.32) 0.18
TT 3 (0.03) 15 (0.07)
Total 113 226
Allele C 188 (0.83) 349 (0.77) 0.07
Allele T 38 (0.17) 103 (0.23)
MMP-3 5A/5A 35 (0.31) 40 (0.18)
5A/6A 57 (0.50) 126 (0.56) 0.015
6A/6A 21 (0.19) 60 (0.26)
Total 113 226
Allele 5A 127 (0.56) 206 (0.46) 0.009
Allele 6A 99 (0.44) 246 (0.54)
MMP-12 AA 89 (0.80) 168 (0.75)
AG 21 (0.19) 53 (0.23) 0.49
GG 1 (0.01) 4 (0.02)
Total 111 225
Allele A 199 (0.90) 389 (0.86) 0.24
Allele G 23 (0.10) 61 (0.14)
CA  coronary aneurysm; MMP  matrix metalloproteinase.
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frequent in the CA group (p  0.009) (Table 3). For the
MMP-2 polymorphism, CC genotype and C allele were
more frequent in the CA group, but the differences were not
statistically significant. By contrast, there was no association
between genotype and allele frequencies for MMP-12
(Table 3). Table 4 shows the results concerning the MMP-9
polymorphism. The allele frequencies were similar to those
previously reported (19,21) and did not differ between the
CA group and the control group. By multivariate analysis,
three variables were independently associated with the
presence of CA: the MMP-3 5A/5A genotype (odds ratio
[OR]  2.23, 95% confidence interval [CI] [1.27 to 3.93]),
a previous MI (OR  1.91, 95% CI [1.14 to 3.20]) and a
history of aortic aneurysm (OR  21.06, 95% CI [2.35 to
188]) (Table 5).
DISCUSSION
The main finding of our study is that the MMP-3 5A/5A
genotype is a potential susceptibility factor for aneurysmal
CAD, reinforcing the involvement of this MMP in vascular
remodeling. In addition, the presence of CAs is associated
with previous MI and aortic aneurysms.
CAs. Coronary aneurysms are defined as localized or dif-
fuse abnormal dilation of the coronary arterial tree. In the
present study, 2.9% of the patients undergoing coronary
angiography had CA; previous studies have reported rates
ranging between 1% and 5% (2–5). Although CA may be
related to specific diseases such as heritable disorders of
connective tissue or inflammatory arteritis, most cases sim-
ply coexist with coronary atherosclerosis, and it has been
suggested that aneurysmal CAD does not represent a
distinct clinical entity but is, rather, a variant of coronary
atherosclerosis (3,4). The mechanisms by which CA may
occur in response to atherosclerosis are unknown. However,
as shown by Virmani et al. (4), the main histological features
of CA are lipid deposition with foam cells, fibrous caps and
extensive destruction of musculoelastic elements of the
media; these findings are similar to those described for
aortic aneurysms. Moreover, in the present study, a signif-
icant association was found between CAs and aortic aneu-
rysms. This suggests that similar processes may, at least in
part, explain the occurrence of CAs and aortic aneurysms.
Proteolysis and aneurysms. The development of aortic
aneurysms is associated with inflammation, tissue-
remodeling and upregulation of MMPs. Matrix metallopro-
teinases can degrade a variety of extracellular proteins such
as elastin, collagen or proteoglycans (27). Increased levels of
MMP-2, MMP-3, MMP-9 and MMP-12 have been found
in the aneurysmal wall (6–10). Recently, gene disruption of
MMP-9 has been found to suppress the development of
experimental abdominal aortic aneurysms (13). Conversely,
a decreased level of TIMP has been found in the aneurysmal
wall (9,11); moreover, Allaire et al. (15) have recently
reported that local expression of TIMP-1 may prevent
aortic aneurysm degeneration and rupture in a rat model.
Taken together, these data suggest that the proteolytic
balance in the vascular wall is a key determinant of aneu-
rysm development.
Polymorphisms of MMP-2, MMP-3, MMP-9 and
MMP-12. Matrix metalloproteinase-2, MMP-3, MMP-9
and MMP-12 genes all have polymorphisms in their pro-
moter regions associated with different transcriptional ac-
tivities in vitro.
The 1,306 C/T MMP-2 polymorphism was recently
described by Price et al. (16). They demonstrated that the
common C 7 T transition at position 1,306 was func-
tional and that the C allele was associated with the higher
promoter activity.
In cultured fibroblasts and vascular smooth muscle cells,
the MMP-3 5A allele is associated with a higher promoter
activity than the 6A allele (18); this should theoretically lead
to a higher proteolytic activity in subjects carrying the 5A
allele. In a recent study, Yoon et al. (21) reported a trend for
a higher frequency of the 5A allele in patients with aortic
aneurysms compared with control patients.
A repeat polymorphism has been identified in the pro-
moter of MMP-9. Variation in the length of this repetitive
element was shown to modulate promoter activity in an in
vitro reporter assay, with the highest promoter activity being
observed in constructs bearing the longest element (23 CA)
(19). The 23 CA repeat allele has been identified as a
susceptibility factor for intracranial aneurysms (19).
Concerning MMP-12, a common polymorphism within
the promoter (A7 G transition at position 82) has been
identified. The polymorphism influences the binding of the
transcription factor AP-1; the higher binding activity of
Table 4. Matrix Metalloproteinase-9 Alleles
Allele Size, bp
(No. of [CA] Repeats)
CA
n (fraction)
Controls
n ( fraction) p Value
147 (14) 132 (0.58) 251 (0.56)
149 (15) 9 (0.04) 9 (0.02)
157 (19) 4 (0.02) 8 (0.01)
159 (20) 2 (0.01) 5 (0.01)
161 (21) 35 (0.15) 85 (0.19) 0.50
163 (22) 34 (0.15) 63 (0.14)
165 (23) 9 (0.04) 22 (0.05)
167 (24) 1 (0.01) 9 (0.02)
Total 226 452
CA  coronary aneurysm.
Table 5. Multivariate Analysis
Variables OR 95% CI p Value
Age 1.00 0.98–1.03 0.83
BMI 1.00 0.97–1.04 0.86
Male gender 2.11 0.93–4.79 0.07
Smoking 1.12 0.60–2.11 0.72
Hypertension 0.81 0.48–1.38 0.44
Diabetes 0.73 0.39–1.38 0.34
Previous MI 1.91 1.14–3.20 0.01
Aortic aneurysm 21.06 2.35–188 0.006
MMP3 5A/5A genotype 2.23 1.27–3.93 0.005
BMI  body mass index; CI  confidence interval; MI  myocardial infarction;
MMP  matrix metalloproteinase; OR  odds ratio.
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AP-1 to the MMP-12 A allele is associated with a higher
MMP-12 promoter activity in in vitro experiments (20).
The present study. This is the first study looking for
genetic susceptibility factors to CA. The MMP-9 and
MMP-12 polymorphisms were not associated with the
occurrence of CA. Although the difference was not statis-
tically significant, the more active C allele of the MMP-2
polymorphism tended to be more frequent in cases than in
controls. Our major finding was that the MMP-3 5A allele
was significantly more frequent in the CA group than in the
control group (p  0.009). Moreover, by multivariate
analysis, the MMP-3 genotype was an independent predic-
tor of CA (OR  2.23, 95% CI [1.27 to 3.93]).
The MMP-3 or stromelysin-1 is an important member of
the metalloproteinase family; various cell types may produce
MMP-3 in the vessel wall: fibroblasts, smooth muscle cells
and macrophages (28). Increased MMP-3 activity could
potentially contribute to the development of structural
alterations in the vessel wall through the degradation of
extracellular matrix proteins such as proteoglycans, laminin,
fibronectin and collagen types III, IV, V and IX (18,27);
furthermore, MMP-3 can amplify the proteolytic effect of
MMP-1 and MMP-9 (29). As stated above, MMP-3
activity is increased in the wall of aortic aneurysms (6);
moreover, MMP-3 activity has been colocalized with mac-
rophages infiltrating the aneurysmal wall (30). Recently,
Carrell et al. (31) examined differences in MMPs between
patients with aortic aneurysm and patients with aortic
atherosclerosis but without aneurysm; among a wide range
of MMPs tested, only MMP-3 was overexpressed in the
aortic aneurysm samples. Finally, in a recent study (14),
reduced aneurysm formation has been observed in mice with
MMP-3 gene inactivation.
Because the MMP-3 5A allele is associated with the
higher promoter activity (18), it is tempting to speculate
that an increased proteolysis in the vessel wall may act as a
susceptibility factor for the development of CA. The obser-
vation by Yoon et al. (21) that the 5A allele was more
frequent in patients with aortic aneurysms compared with
control patients is consistent with our results. Although our
results do not imply that MMP-3 plays a role in CA, one
attractive hypothesis would be that the higher production of
MMP-3 associated with the 5A allele may lead to an
increased remodeling process of coronary arteries in re-
sponse to atherosclerosis. Previously published studies on
the MMP-3 5A/6A polymorphism tend to support this
hypothesis; while the 5A allele has been associated with
acute coronary syndromes (22) (a situation in which in-
creased proteolysis may also be important), the less active
6A allele has been associated with angiographic progression
of CAD (17,18) or restenosis after balloon angioplasty (23)
(two situations in which decreased proteolysis and subse-
quent matrix deposition may play a role). Finally, the recent
observation that high circulating levels of MMP-3 are
associated with coronary lesions in Kawasaki disease (32)
also supports an important role for MMP-3 in the patho-
genesis of CAs.
We observed that CA was independently associated with
MI; this finding is concordant with previously published
studies (2,3). The mechanisms underlying this association
are unknown, but at least two plausible hypotheses can be
advanced. First, CA have been associated with abnormal
blood flow (33), which may increase the risk of thrombus
formation with subsequent embolization or in situ throm-
bosis; recent studies have also suggested that the aneurysmal
wall may be a source of thrombogenic substances (34).
Second, as discussed above, CA development may simply
reflect an increased proteolytic activity in the arterial wall.
This increased proteolysis could theoretically predispose to
an increased risk of plaque rupture and a subsequent acute
coronary event (1).
A history of aortic aneurysm was more frequently ob-
served in the CA group. This finding should be interpreted
with caution because it was not the primary objective of our
study; moreover, systematic screening for aortic aneurysm
was not performed. However, the fact that a history of aortic
aneurysm was significantly more frequent in the CA group
(OR  21.06, 95% CI [2.35 to 188]) suggests that both
processes share common physiopathologic mechanisms that
are likely to be determined on a patient-related basis rather
than on a lesion-(local) related basis. A recent study
showing an ubiquitous elevation of MMP-2 expression in
the vasculature of patients with abdominal aneurysms sup-
ports this hypothesis (35). Patients with multiple aneurysms
(i.e., aortic, coronary or other locations) would indeed be
interesting candidates for future research on genetic risk
factors for atherosclerotic aneurysmal disease. In addition, a
prospective study should be designed to test whether sys-
tematic screening for asymptomatic aortic aneurysm is a
beneficial and cost-effective strategy in patients with CAs.
Study limitations. The association of an MMP polymor-
phism with CA does not necessary imply that the genetic
variation is, in itself, responsible for the increased risk of
CA. In addition, the increased levels of MMPs in the
aneurysmal wall may depend not only on an increased
synthesis from more active alleles but also on an increased
infiltration of MMPs producing cells such as monocytes and
macrophages. However, the present study benefited from a
prospective recruitment and from a candidate gene ap-
proach. We selected four genes on the basis of their
relevance in the pathophysiology of aneurysms, and all the
polymorphisms selected for this study exhibit different
transcriptional activities in vitro.
Finally, although our study clearly supports an association
between the MMP-3 genotype and CA, the limited number
of patients with CA does not allow us to exclude an
influence of the other polymorphisms on this abnormal
form of remodeling; thus, our findings should be taken as
hypothesis-generating rather than conclusive. With a sta-
tistical power of 80% and a significance value of 0.05, the
sample size of this study allowed us to detect a 9% difference
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in the frequency of the MMP-2 T allele, a 6% difference in
the frequency of the MMP-9 (CA) 23 allele and a 7%
difference in the frequency of the MMP-12 G allele.
However, we prospectively analyzed 3,862 coronary angiog-
raphy procedures to select the CA group; the design of
larger studies would imply a multicentric recruitment.
CONCLUSIONS
The MMP-3 5A allele is associated with the occurrence of
CA. This supports the hypothesis that an increased prote-
olysis in the arterial wall may act as a susceptibility factor for
the development of CA in patients with coronary athero-
sclerosis although other mechanisms cannot be excluded.
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